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Treatment with high-dose Interleukin-2 (IL-2) has been
associated with long-term survival in small proportion
of metastatic melanoma patients. We recently reported
a median survival of 15.6 months, and a 20% 5-year sur-
vival rate for 150 such patients who were hospitalized
for high-dose i.v. IL-2 between May 1987 and April
2010. [1] A recent report showed a survival advantage
for the addition of gp100 vaccine plus high-dose IL-2
compared to treatment with IL-2 alone [2]. We were
aware that several of our IL-2 patients had also received
patient-specific tumor cell vaccines derived from autolo-
gous tumor cell lines. We wished to determine whether
this may have contributed to their high 5-year survival
rate. Comparison of existing data bases revealed that 27
of the 150 IL-2 patients had also received a patient-spe-
cific vaccine; 123 had not. The table below (Table 1)
summarizes survival data, which was calculated from the
date IL-2 was initiated. Survival was much better in
patients who received a patient-specific vaccine in addi-
tion to IL-2 (p<0.001). That group was also younger,
but age was not a predictor of survival in as much as
median and 5-year survival rates were not dissimilar:
14.1 months and 23% for patients age <50 years at the
time of IL-2, compared to 15.9 months and 17% for
patients > age of 50 (NSD). Of the 27 vaccine patients,
7 started vaccine therapy an average of 8.7 mos. before
receiving IL-2 (range 2.4 to 40 mos.) and 20 received
vaccine a median of 14.2 months after starting IL-2
(range 1 to 42 mos.); 12 received injections of irradiated
autologous tumor cells and 15 received injections
of dendritic cells loaded with antigens from irradi-
ated autologous tumor cells, and suspended in 500
microgram GM-CSF. Survival was longer in patients
who received IL-2 first (5-yr survival 55% vs 14%), and
in patients who received the dendritic cell vaccine (5-yr
survival 53% vs 33%). This analysis suggests that receipt
of high-dose IL-2 followed by a patient specific vaccine
results in better survival than IL-2 alone, but the limita-
tions of such a retrospective analysis, and the risk of
confounding unintended bias, are significant.
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Table 1
Therapy IL-2 IL-2 + Vaccine
Portion female 58% 59%
Median age at diagnosis 50 yrs 40 yrs
Median age at IL-2 54 yrs 44 yrs
Median age at vaccine N/A 47
Median survival from IL-2 12.8 mos 40.3 mos
5-year survival from IL-2 14% 44%
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